buthionine sulfoximine has been researched along with Cognition Disorders in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castagné, V; Cuénod, M; Do, KQ | 1 |
| Castagné, V; Cuenod, M; Do, KQ; Rougemont, M | 1 |
| Kise, M; Mamiya, T; Morikawa, K | 1 |
| Anderson, CP; Bleyer, WA; Cairncross, JG; Cloughesy, T; Doolittle, ND; Eck, SL; Guastadisegni, P; Hall, WA; Muldoon, LL; Neuwelt, EA; Patel, SJ; Peereboom, D; Siegal, T | 1 |
4 other study(ies) available for buthionine sulfoximine and Cognition Disorders
| Article | Year |
|---|---|
An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development.
Topics: Aging; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain Chemistry; Buthionine Sulfoximine; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Embryonic and Fetal Development; Enzyme Inhibitors; Exploratory Behavior; Female; Glutathione; Lipid Peroxidation; Male; Maze Learning; Medulla Oblongata; Motor Activity; Pharmacy and Therapeutics Committee; Piperazines; Pons; Pregnancy; Psychomotor Performance; Rats; Rats, Mutant Strains; Recognition, Psychology; Schizophrenia; Sex Characteristics; Time Factors | 2004 |
Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia.
Topics: Animals; Ascorbic Acid Deficiency; Body Weight; Brain; Brain Chemistry; Buthionine Sulfoximine; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Enzyme Inhibitors; Female; Glutathione; Male; Maze Learning; Membrane Proteins; Nerve Tissue Proteins; Neurons; Oxidative Stress; Piperazines; Rats; Rats, Mutant Strains; Rats, Wistar; Recognition, Psychology; Schizophrenia; Synaptic Transmission | 2004 |
Ferulic acid attenuated cognitive deficits and increase in carbonyl proteins induced by buthionine-sulfoximine in mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Buthionine Sulfoximine; Cognition Disorders; Coumaric Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exploratory Behavior; Free Radical Scavengers; Male; Maze Learning; Mice; Mice, Inbred ICR; Protein Carbonylation | 2008 |
Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Bone Marrow Diseases; Bone Marrow Transplantation; Brain Neoplasms; Buthionine Sulfoximine; Child; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Drug Synergism; Genetic Therapy; Genetic Vectors; Glioma; Glutathione; Guinea Pigs; Hearing Loss, Sensorineural; Hematopoietic Stem Cell Transplantation; Humans; Hypertonic Solutions; Lymphoma, Non-Hodgkin; Meningeal Neoplasms; Multicenter Studies as Topic; Neuroblastoma; Oligodendroglioma; Permeability; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |